All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Plays a role in the protection against host NK-cell cytotoxicity by upregulating the cell surface expression of HLA-E independent of TAP (HLA-E has an inhibitory effect on the cytotoxic activity of the NK cell). Promotes also cell surface expression of UL18, another viral protein involved in NK-cell evasion.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-C255Z | Human anti-UL40 T cell receptor (KK50.4), pCDTCR1 | CMV | KK50.4 | Human | VMAPRTLIL | HLA-E*0103 | Lentiviral | |
TCR-YC1281 | Human anti-UL40 T cell receptor ((GF4)-1), pCDTCR1 | HCMV | GF4 | Human | VMAPRTLIL | HLA-E | Lentiviral vector | |
TCR-YC1282 | Human anti-UL40 T cell receptor ((GF4)-2), pCDTCR1 | GF4 | Human | VMAPRTLVL | HLA-E | Lentiviral vector | ||
TCR-YF042 | Human anti-UL40 T cell receptor (GF4), pCDTCR1 | CMV | GF4 | Human | VMAPRTLVL | HLA-E | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION